Lineage Cell Therapeutics, Inc.
LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyteā¦ read more
Healthcare
Biotechnology
33 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.76
Price+1.74%
$0.03
1Y
Price
Market Cap
$404.860m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-172.5%
EBITDA Margin-1101.8%
Net Profit Margin-200.8%
Free Cash Flow MarginRevenue
$10.914m
+14.9%
1y CAGR-6.0%
3y CAGR+64.8%
5y CAGREarnings
-$40.910m
-119.8%
1y CAGR-29.3%
3y CAGR-12.3%
5y CAGREPS
-$0.18
-100.0%
1y CAGR-18.3%
3y CAGR-3.2%
5y CAGRBook Value
$47.112m
$90.799m
Assets$43.687m
Liabilities$2.154m
DebtDebt to Assets
2.4%
-0.1x
Debt to EBITDAFree Cash Flow
-$22.849m
+3.4%
1y CAGR-1534.6%
3y CAGR-1125.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company